Omnicell (NASDAQ:OMCL) Releases Q1 2025 Earnings Guidance

Omnicell (NASDAQ:OMCL - Get Free Report) updated its first quarter 2025 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 0.150-0.250 for the period, compared to the consensus estimate of 0.210. The company issued revenue guidance of $255.0 million-$265.0 million, compared to the consensus revenue estimate of $260.2 million. Omnicell also updated its FY 2025 guidance to 1.650-1.850 EPS.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on OMCL shares. Wells Fargo & Company reduced their target price on shares of Omnicell from $49.00 to $40.00 and set an "equal weight" rating on the stock in a research note on Monday, January 13th. Bank of America dropped their target price on Omnicell from $54.00 to $46.00 and set a "neutral" rating for the company in a research report on Monday, January 6th. Benchmark restated a "buy" rating and set a $62.00 price objective on shares of Omnicell in a report on Tuesday, February 4th. JPMorgan Chase & Co. reduced their target price on Omnicell from $44.00 to $36.00 and set a "neutral" rating on the stock in a research note on Thursday, March 20th. Finally, StockNews.com lowered shares of Omnicell from a "buy" rating to a "hold" rating in a research note on Monday, March 24th. Five equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, Omnicell has an average rating of "Hold" and an average target price of $51.00.

Remove Ads

Omnicell Stock Up 1.6 %

Omnicell stock traded up $0.56 during midday trading on Tuesday, hitting $35.52. 117,795 shares of the company's stock were exchanged, compared to its average volume of 517,158. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37. The company has a market cap of $1.66 billion, a PE ratio of 131.73, a P/E/G ratio of 7.53 and a beta of 0.85. The firm has a 50-day moving average of $38.86 and a two-hundred day moving average of $42.52. Omnicell has a 12 month low of $25.12 and a 12 month high of $55.75.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. As a group, analysts expect that Omnicell will post 1.09 earnings per share for the current fiscal year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.